Investigational drug · Phase 3
RT001
Also called: Deuterated linoleic acid
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Infantile Neuroaxonal Dystrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2021 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "RT001"
First trial start
2018
Nov 5, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RT001", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Infantile Neuroaxonal Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "RT001" as an intervention, largest first.
- A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsPivotal-lookingCompleted
Revance Therapeutics, Inc.Industry
NCT01124552 · 180 participants · Start Apr 2010 · Primary completion Jul 2010
Drug: RT001 Botulinum toxin type A (Dose A); RT001 Botulinum Toxin Type A (Dose B) and 1 more · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: Coral Gables, Florida
Revance Therapeutics, Inc.Industry
NCT01064518 · 90 participants · Start Jan 2010 · Primary completion Jul 2010
Drug: Botulinum Toxin Type A; Placebo (Dose B) · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: Coral Gables, Florida
Revance Therapeutics, Inc.Industry
NCT00968825 · 73 participants · Start Jul 2009 · Primary completion Oct 2009
Drug: Botulinum Toxin Type A; Placebo · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: San Francisco, California
Revance Therapeutics, Inc.Industry
NCT00907387 · 72 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: RT001; RT001 · For: Lateral Canthal Lines
Sites: Birmingham, Alabama; San Francisco, California; Coral Gables, Florida · 9 sites in all
- A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's AtaxiaPivotal-lookingCompleted
Biojiva LLCIndustry
NCT04102501 · 65 participants · Start Oct 30, 2019 · Primary completion Aug 23, 2021
Drug: RT001; Placebo · For: Friedreich's Ataxia
Sites: Long Beach, California; Los Angeles, California; Gainesville, Florida · 6 sites in all
Revance Therapeutics, Inc.Industry
NCT00888914 · 60 participants · Start Nov 2008 · Primary completion Jan 2009
Drug: RT001; RT001 and 2 more · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: San Francisco, California; New York, New York; White Plains, New York · 4 sites in all
Biojiva LLCIndustry
NCT04762589 · 43 participants · Start Mar 10, 2021 · Primary completion Jun 28, 2022
Drug: RT001; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Tartu, Estonia; Riga, Latvia; Utrecht, Netherlands · 4 sites in all
Revance Therapeutics, Inc.Industry
NCT01124565 · 40 participants · Start May 2010 · Primary completion Jul 2010
Drug: RT001 · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: Birmingham, Alabama; San Diego, California; Omaha, Nebraska
- RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSYStatus unknown
Biojiva LLCIndustry
NCT04937530 · 40 participants (planned) · Start Jun 23, 2021 · Primary completion Jul 30, 2022
Drug: RT001; Placebo · For: Progressive Supranuclear Palsy
Sites: Munich, Germany
Revance Therapeutics, Inc.Industry
NCT00968942 · 36 participants · Start Aug 2009 · Primary completion Oct 2009
Drug: Botulinum Toxin Type A; Placebo · For: Lateral Canthal Lines; Crow's Feet; Facial Wrinkles
Sites: Coral Gables, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Clostridioides difficile-derived membrane vesicles induce pro-apoptotic effects in human intestinal epithelial cells and macrophages in vitro.
Azimirad M, Sabzehali F, Mashhoori Vayghan M, et al. · Mol Biol Rep 2026
- Tracking Clostridioides difficile in Germany: Active prospective surveillance progress and molecular epidemiological trends.
Abdrabou AM, Schneider JS, Berger FK, et al. · Int J Med Microbiol 2026
- Molecular epidemiology of Clostridioides difficile clinical isolates in a tertiary-care hospital of northern Mexico: single-center real-life study.
Salas-Treviño D, Flores-Treviño S, Bocanegra-Ibarias P, et al. · Anaerobe 2026
- Antibiotic resistance profiles and molecular characteristics of Clostridioides difficile PCR ribotypes in patients with colorectal polyps.
Azimi T, Asli M, Fallahzadeh E, et al. · BMC Microbiol 2026
- Molecular epidemiology and antimicrobial resistance profiles of Clostridioides difficile in Xi'an.
Luan Y, Yang Y, Tian Y, et al. · Front Microbiol 2026
- Clostridioides difficile in chicken fresh meat at retail in France.
Le Maréchal C, Ehmig M, Reboul G, et al. · Anaerobe 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.